Table 3.
The relationship of last cotesting results with histology and cancer stage. Abbreviations: SCC, squamous cell carcinoma; ADC, adenocarcinoma; HPV, human papillomavirus; Cyto, cytology
| HPV+ (n=532) | HPV− (n=91) | Cyto+ (n=514) | Cyto- (n=108) | HPV−/Cyto− (n=51) | HPV−/Cyto+ (n=40) | HPV+/Cyto− (n=58) | HPV+/Cyto+ (n=474) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | %col | n | %col | n | %col | n | %col | n | %col | n | %col | n | %col | n | %col | |
| Histology | ||||||||||||||||
|
| ||||||||||||||||
| SCC | 298 | 56.0% | 53 | 58.2% | 309 | 60.1% | 42 | 38.9% | 27 | 52.9% | 26 | 65.0% | 15 | 25.9% | 283 | 59.7% |
| ADC | 185 | 34.8% | 27 | 29.7% | 158 | 30.7% | 54 | 50.0% | 17 | 33.3% | 10 | 25.0% | 37 | 63.8% | 148 | 31.2% |
| Other | 9 | 1.7% | 10 | 11.0% | 8 | 1.6% | 11 | 10.2% | 7 | 13.7% | 3 | 7.5% | 4 | 6.9% | 5 | 1.1% |
| Unknown‡ | 40 | 7.5% | 1 | 1.1% | 39 | 7.6% | 2 | 1.9% | 0 | 0.0% | 1 | 2.5% | 2 | 3.5% | 38 | 8.0% |
|
| ||||||||||||||||
| Stage | ||||||||||||||||
|
| ||||||||||||||||
| Localized | 302 | 56.8% | 31 | 34.1% | 285 | 55.4% | 48 | 44.4% | 14 | 27.5% | 17 | 42.5% | 34 | 58.6% | 268 | 56.5% |
| Regional (all) | 67 | 12.6% | 26 | 28.6% | 72 | 14.0% | 21 | 19.4% | 15 | 29.4% | 11 | 27.5% | 6 | 10.3% | 61 | 12.9% |
| Distant | 15 | 2.8% | 14 | 15.4% | 20 | 3.9% | 9 | 8.3% | 9 | 17.7% | 5 | 12.5% | 0 | 0.0% | 15 | 3.2% |
| Unknown/Missing | 148 | 27.8% | 20 | 22.0% | 137 | 26.7% | 31 | 28.7% | 13 | 25.5% | 7 | 17.5% | 18 | 31.0% | 130 | 27.4% |